• PDF: Delivered by email usually within 48 UK business hours.

GlaxoSmithKline plc
Market Share Analysis

  • Publication Date:June 2011
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:121

GlaxoSmithKline plc Market Share Analysis

GlaxoSmithKline plc Market Share Analysis

Summary

GlobalData's new report, "GlaxoSmithKline plc Market Share Analysis" provides in-depth information on GlaxoSmithKline plc's market position in the metered dose inhaler devices market. The report also provides data and information on the overall competitive landscape within the metered dose inhaler devices market. The report is supplemented with global corporate-level profile with information on the company's business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

  • Global company shares (in Revenues) information for the metered dose inhaler devices market.
  • GlaxoSmithKline plc's company shares (in Revenues) information for all the key countries the company has presence in - India, Japan, China, Australia, United Kingdom, France, Germany, Spain, Italy, United States, Canada and Brazil.
  • GlaxoSmithKline plc's company shares (in Revenues) information for the metered dose inhaler devices market.
  • All the key data-points are for 2010 and cover all the key regions - North America, Middle East and Africa, Europe, Asia-Pacific and South and Central America.
  • Global corporate-level profile with information on the company's business segments, major products and services, competitors, and locations and subsidiaries.
  • The company profile is also supplemented with a SWOT Analysis with in-depth information and analysis of the company's value proposition and the business climate it operates in.
  • Comprehensive coverage of the latest financial deals involving the company and its subsidiaries, if any.

Reasons to buy

  • Develop sales and marketing strategies by identifying who-stands-where in the markets, GlaxoSmithKline plc's operates in.
  • Plan your competition strategies by identifying the company's shares in the markets and geographic regions it operates in.
  • Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are involved in.
  • Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in the report.
  • Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not limited to GlaxoSmithKline plc's market positions.

This report covers the following industry codes:

  • SIC Code: 2834
  • NAICS Code: 325412
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets/Categories Covered
    • 3.1 Metered Dose Inhaler Devices
  • 4 Company Snapshot
    • 4.1 Key Information
    • 4.2 Company Overview
    • 4.3 Financial Performance
    • 4.4 SWOT Snapshot
    • 4.5 Business Overview
    • 4.6 Major Products and Services
      • 4.6.1 Overview
  • 5 History
  • 6 SWOT Analysis
    • 6.1 Overview
    • 6.2 GlaxoSmithKline plc Strengths
      • 6.2.1 Diversified Product Portfolio
      • 6.2.2 Focused Research and Development Capabilities
      • 6.2.3 Global Manufacturing and Supply Network
      • 6.2.4 Strong Growth Prospects
    • 6.3 GlaxoSmithKline plc Weaknesses
      • 6.3.1 Patent Infringement Claims
      • 6.3.2 Limited Liquidity Position
      • 6.3.3 Increasing Operating Expenses
    • 6.4 GlaxoSmithKline plc Opportunities
      • 6.4.1 New Product Launches and Approval
      • 6.4.2 Strategic Agreements
      • 6.4.3 Growth in Emerging Markets
      • 6.4.4 Target Indications - Market Potential
    • 6.5 GlaxoSmithKline plc Threats
      • 6.5.1 Competitive Pressures
      • 6.5.2 Uncertain R&D Outcomes
      • 6.5.3 Increase in Prevalence of Counterfeit Drugs
      • 6.5.4 Growing Parallel Trade
  • 7 Competitors
  • 8 Competitive Landscape
    • 8.1 Metered Dose Inhaler Devices, Global, Market Share (%), 2010
  • 9 GlaxoSmithKline plc Medical Equipment Market Share Analysis
    • 9.1 GlaxoSmithKline plc, Metered Dose Inhaler Devices, Global, Market Share (2010)
    • 9.2 GlaxoSmithKline plc, Asia-Pacific, Market Share (2010)
    • 9.3 GlaxoSmithKline plc, Europe, Market Share (2010)
    • 9.4 GlaxoSmithKline plc, Middle East and Africa, Market Share (2010)
    • 9.5 GlaxoSmithKline plc, North America, Market Share (2010)
    • 9.6 GlaxoSmithKline plc, South and Central America, Market Share (2010)
  • 10 Key Employees
  • 11 Key Employee Biographies
  • 12 Company Statement
  • 13 Locations And Subsidiaries
    • 13.1 Head Office
    • 13.2 Other Locations & Subsidiaries
  • 14 Financial Deals Landscape
    • 14.1 GlaxoSmithKline plc, Deals Volume Summary, 2006 to YTD 2011
  • 15 GlaxoSmithKline plc, Deals Summary By Region, 2006 to YTD 2011
  • 16 GlaxoSmithKline plc Detailed Deal Summary
    • 16.1 Venture Financing
      • 16.1.1 Freedom Meditech Secures $0.25 Million In Second Round Of Series A Financing
      • 16.1.2 diaDexus Secures $9.2 Million In Series F Financing
      • 16.1.3 diaDexus Secures $40 Million In Series E Funding
    • 16.2 Partnerships
      • 16.2.1 GlaxoSmithKline Enters Into An Agreement With Labtec
      • 16.2.2 Response Genetics Signs Licensing Agreement With GlaxoSmithKline
      • 16.2.3 Insulet Enters Into Distribution Agreement With GlaxoSmithKline
      • 16.2.4 bioMerieux Signs Co-Development Agreement With GlaxoSmithKline
      • 16.2.5 Abbott Laboratories Enters Into An Agreement With GlaxoSmithKline
      • 16.2.6 bioMerieux Enters Into An Agreement With GlaxoSmithKline
      • 16.2.7 GlaxoSmithKline Signs Co-Development Agreement With Enigma Diagnostics
      • 16.2.8 DermTech International Enters Into Co-Development Agreement With Stiefel Laboratories
      • 16.2.9 OncoMethylome Sciences Enters Into Collaboration With GlaxoSmithKline Biologicals
    • 16.3 Divestiture - Company
      • 16.3.1 Thermo Fisher Scientific Acquires Qualigens Fine Chemicals GlaxoSmithKline Pharmaceuticals
    • 16.4 Acquisition
      • 16.4.1 Enigma Diagnostics To Receive Equity Investment From GlaxoSmithKline
      • 16.4.2 GlaxoSmithKline Acquires CNS
  • 17 Recent Developments
    • 17.1 Strategy And Business Planning
      • 17.1.1 Oct 18, 2010: GSK, Fondazione Telethon And Fondazione San Raffaele Partner To Develop Gene Therapy For Rare Diseases
      • 17.1.2 Aug 04, 2010: GlaxoSmithKline And Amplimmune Form Research Partnership
      • 17.1.3 Aug 03, 2010: Five Prime Partners With GSK To Discover Innovative Biologics For Skeletal Muscle Disorders
      • 17.1.4 Mar 31, 2010: GSK And Isis Pharmaceuticals Collaborate On RNA Therapeutics For Rare And Infectious Disease
      • 17.1.5 Feb 22, 2010: GlaxoSmithKline plans to construct biotech plant in UK
      • 17.1.6 Feb 05, 2010: GSK to shut Italian R&D center, eliminate 500 jobs
      • 17.1.7 Jan 31, 2010: GSK to axe up to 4,000 jobs
      • 17.1.8 Dec 01, 2009: GSK Extends Strategic Collaboration With Aspen
      • 17.1.9 Nov 12, 2009: Astex Forms Drug Discovery Partnership With GlaxoSmithKline
      • 17.1.10 Nov 10, 2009: Lonza To Manufacture Arzerra
      • 17.1.11 Nov 10, 2009: Lonza To Manufacture Antibody Arzerra
      • 17.1.12 Nov 06, 2009: Sagentia To Improve Manufacturing Efficiency Of UK Pharma Firms
      • 17.1.13 Nov 03, 2009: GlaxoSmithKline, Pfizer Establish ViiV Healthcare
      • 17.1.14 Oct 13, 2009: GlaxoSmithKline, Prosensa Form Alliance Against DMD
      • 17.1.15 Oct 13, 2009: GSK Collaborates With UK Government, Wellcome Trust, EEDA
      • 17.1.16 Oct 07, 2009: Galapagos Reaches First Milestone In Anti-Infectives Alliance With GSK
    • 17.2 Financial Announcements
      • 17.2.1 Oct 21, 2010: GSK Reports Net Income Of GBP1.3 Billion For Q3 2010
      • 17.2.2 Jul 21, 2010: GSK Reports Net Loss Of GBP304 Million For Q2 2010
      • 17.2.3 Apr 28, 2010: GSK Reports Net Income Of GBP1.4 Billion For Q1 2010
      • 17.2.4 Feb 04, 2010: GSK Reports Net Income Of GBP1.7 Billion For Q4 2009
      • 17.2.5 Feb 04, 2010: GlaxoSmithKline Reports Profit Of GBP5.6 Billion In 2009
      • 17.2.6 Oct 28, 2009: GSK Reports 15% Increase In Q3 Revenue
      • 17.2.7 Oct 28, 2009: GSK Q3 2009 Net Profit Increases
      • 17.2.8 Jul 22, 2009: GlaxoSmithKline Reports Turnover Of GBP6.74 Billion In Q2 2009
      • 17.2.9 Jul 22, 2009: GSK Reports Net Profit Of GBP1.43 Billion For Q2 2009
      • 17.2.10 Apr 22, 2009: GlaxoSmithKline Posts profit Of GBP1.13 billion In Q1 2009
      • 17.2.11 Apr 22, 2009: GSK Q1 2009 Net Profit Declines
      • 17.2.12 Feb 05, 2009: GlaxoSmithKline Declares Interim Dividend
      • 17.2.13 Feb 05, 2009: GlaxoSmithKline Reports 2008 Results
      • 17.2.14 Feb 05, 2009: GSK Q4 2008 Net Profit Declines
      • 17.2.15 Oct 22, 2008: GlaxoSmithKline Reports 3Q 2008 Results
      • 17.2.16 Oct 22, 2008: GlaxoSmithKline Declares Interim Dividend
    • 17.3 Research And Development
      • 17.3.1 May 12, 2011: University And Pharmaceutical Industry Create Center For Inflammation Research
      • 17.3.2 May 12, 2011: GlaxoSmithKline And Gilead Sciences AIDS Drugs Cut Transmission To Partners By 96%, Study Shows
      • 17.3.3 Nov 12, 2010: GlaxoSmithKline And Fiocruz Partner To Develop Medicines For Neglected Tropical Diseases
      • 17.3.4 Aug 16, 2010: MMV To Contribute Patents To Pool For Open Innovation Against Neglected Tropical Diseases
      • 17.3.5 Jul 29, 2010: GSK Exercises Option On Anacor's New Antibiotic For Treatment Of Gram-Negative Infections
      • 17.3.6 Jul 02, 2010: GSK And EDB Commit $35 Million In Funding To Support Research In Green And Sustainable Manufacturing In Singapore
      • 17.3.7 May 17, 2010: ImaginAb Partners With GSK For Development Of Clinical Therapeutic Antibody
      • 17.3.8 Apr 29, 2010: EyeGate Pharma Partners With GSK To Deliver Medicines Using EyeGate II Delivery System
      • 17.3.9 Mar 18, 2010: Global Partners Collaborate To Speed Development Of New TB Drug Combinations
      • 17.3.10 Mar 03, 2010: to-BBB, GSK To Collaborate On Brain Delivery Of Biologic Product
      • 17.3.11 Dec 09, 2009: Cytokinetics, GSK Terminate Collaboration And Licensing Agreement
      • 17.3.12 Nov 17, 2009: bioMerieux Seals Agreement With GSK
      • 17.3.13 Oct 27, 2009: GSK Provides Update On Pandemic 2009 Influenza Vaccine
      • 17.3.14 Jun 07, 2009: GSK's Syncria To Improve Glucose Control, Reduce Weight
      • 17.3.15 Jun 02, 2009: Concert Pharmaceuticals And GSK Form Alliance To Develop New Deuterium Modified Drugs
      • 17.3.16 May 23, 2009: US To Grant $800m To Pharma Majors For Swine Flu Vaccine
    • 17.4 Corporate Communications
      • 17.4.1 May 11, 2010: GSK Appoints Patrick Vallance To Executive Leadership Team
      • 17.4.2 Feb 04, 2010: GSK Appoints Philippe Fauchet As President Of GSK Japan
      • 17.4.3 Feb 02, 2009: GSK Announces Board Changes
      • 17.4.4 Feb 02, 2009: GlaxoSmithKline Announces Board Changes
      • 17.4.5 Jan 30, 2009: GSK Appoints Deirdre Connelly As President, North American Pharmaceuticals
      • 17.4.6 Sep 09, 2008: GlaxoSmithKline Appoints CMO
      • 17.4.7 Sep 09, 2008: GSK Appoints Ellen Strahlman As Chief Medical Officer
      • 17.4.8 Jul 22, 2008: GlaxoSmithKline Appoints Senior Vice President, General Counsel
      • 17.4.9 Dec 07, 2007: GlaxoSmithKline Announces Board And Management Changes
    • 17.5 Legal and Regulatory
      • 17.5.1 May 26, 2011: Genetic Technologies Files New Patent Infringement Suit In US
      • 17.5.2 Jan 17, 2011: GlaxoSmithKline Announces Q4 2010 Legal Charge
      • 17.5.3 Oct 26, 2010: GlaxoSmithKline To Plead Guilty & Pay $750 Million To Resolve Criminal And Civil Liability Regarding Manufacturing Deficiencies At Puerto Rico Plant
      • 17.5.4 Oct 18, 2010: Mylan To Appeal Court Decision In Generic Paroxetine Hydrochloride CR Case
      • 17.5.5 May 20, 2010: GSK Provides Update On German Patent Litigation Concerning Seretide
      • 17.5.6 Apr 12, 2010: Glenmark Generics Settles Paragraph IV Litigation With GSK
      • 17.5.7 Jun 26, 2009: GSK Provides Update On Seretide Litigation
    • 17.6 Government and Public Interest
      • 17.6.1 May 12, 2011: GlaxoSmithKline And Gilead Sciences AIDS Drugs Cut Transmission To Partners By 96%, Study Shows
      • 17.6.2 Feb 07, 2011: GSK Revises US Avandia Label To Include New Restrictions On Use
      • 17.6.3 Nov 16, 2010: GSK Reports New Study Findings Show No Benefit Of Prescription Omega-3 Fatty Acids In Prevention Of Recurrent Symptomatic Atrial Fibrillation
      • 17.6.4 Sep 23, 2010: FDA Restricts Access To GSK's Avandia
      • 17.6.5 Jun 02, 2010: GSK Announces Revised Product Labels For Serevent And Advair
      • 17.6.6 May 19, 2010: New Research At GSK Identifies Promising Approach To Discover Medicines Against Malaria
      • 17.6.7 May 07, 2010: GSK Issues Statement On FDA Advisory Committee Meeting On Rotavirus vaccines
      • 17.6.8 Apr 13, 2010: GSK Honors Healthcare Nonprofits With $360,000 In Awards
      • 17.6.9 Mar 23, 2010: GSK Joins Global Vaccine Alliance To Help Prevent Children From Contracting Pneumococcal Disease
      • 17.6.10 Feb 10, 2010: GSK Introduces CARES by GSK To Improve Patient Access To GSK Oncology, Specialty Medicines
      • 17.6.11 Jan 29, 2010: US Attorney General Announces $5.8 Million In Civil Penalties Against GSK
      • 17.6.12 Jan 26, 2010: GSK Grants $360,000 To Nine Healthcare Nonprofits
      • 17.6.13 Jan 18, 2010: GSK Provides $135,000 Grant To Philadelphia's Breast Health Program
      • 17.6.14 Nov 11, 2009: FDA Approves GSK's H1N1 vaccine
      • 17.6.15 Nov 06, 2009: GSK Receives Prequalification From WHO For Synflorix
      • 17.6.16 Nov 06, 2009: FDA Extends Review Date For Gabapentin Enacarbil
      • 17.6.17 Nov 02, 2009: GSK, Valeant Provide Updates On NDA For Retigabine
      • 17.6.18 Oct 28, 2009: US Court Rejects Litigation Against NutriSystem
    • 17.7 Other Significant Developments
      • 17.7.1 Jul 26, 2010: GlaxoSmithKline To Implement New Compensation Program For US Sales Professionals
      • 17.7.2 Jul 15, 2010: GSK Expects To Record Legal Charge Of GBP1.57 Billion For Q2 2010
      • 17.7.3 Jul 15, 2010: GSK Provides Legal Update
      • 17.7.4 May 20, 2010: Mahindra Satyam BPO Secures Five-Year Contract With GlaxoSmithKline
      • 17.7.5 Mar 29, 2010: GSK Offers Free Vaccines To Uninsured Adults
      • 17.7.6 Jan 29, 2010: GSK Donates $1.4 Million In Medicines For Haiti Relief Efforts
      • 17.7.7 Oct 06, 2009: GSK Unveils Update On Government Orders For H1N1 Vaccine
      • 17.7.8 Sep 28, 2009: GlaxoSmithKline Enters Into Agreement With UPCH
      • 17.7.9 Dec 31, 2008: GlaxoSmithKline Spends $2 Million On Lobbying In 3Q 2008
  • 18 Appendix
    • 18.1 Research Methodology
    • 18.2 Secondary Research
    • 18.3 Primary Research
    • 18.4 Models
    • 18.5 Forecasts
    • 18.6 Expert Panels
    • 18.7 GlobalData Consulting
    • 18.8 Currency Conversion
    • 18.9 Contact Us
    • 18.10 Disclaimer
    • 1.1 List of Tables
      • Table 1: GlaxoSmithKline plc, Key Facts, 2010
      • Table 2: GlaxoSmithKline plc, SWOT Analysis, 2010
      • Table 3: Metered Dose Inhaler Devices, Global, Company Share by Revenue ($m), 2010
      • Table 4: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Global, Revenue ($m) and Market Share (%), 2010
      • Table 5: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Asia-Pacific, Revenue ($m) and Market Share (%), 2010
      • Table 6: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Europe, Revenue ($m) and Market Share (%), 2010
      • Table 7: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Middle East and Africa, Revenue ($m) and Market Share (%), 2010
      • Table 8: GlaxoSmithKline plc, Metered Dose Inhaler Devices, North America, Revenue ($m) and Market Share (%), 2010
      • Table 9: GlaxoSmithKline plc, Metered Dose Inhaler Devices, South and Central America, Revenue ($m) and Market Share (%), 2010
      • Table 10: GlaxoSmithKline plc, Key Employees
      • Table 11: GlaxoSmithKline plc, Other Locations
      • Table 12: GlaxoSmithKline plc, Subsidiaries
      • Table 13: GlaxoSmithKline plc, Deals Volume Summary, 2006 to YTD 2011
      • Table 14: GlaxoSmithKline plc, Deals Summary By Region, 2006 to YTD 2011
      • Table 15: GlaxoSmithKline plc, Deals Summary, 2006 to YTD 2011
      • Table 16: Freedom Meditech Secures $0.25 Million In Second Round Of Series A Financing
      • Table 17: diaDexus Secures $9.2 Million In Series F Financing
      • Table 18: diaDexus Secures $40 Million In Series E Funding
      • Table 19: GlaxoSmithKline Enters Into An Agreement With Labtec
      • Table 20: Response Genetics Signs Licensing Agreement With GlaxoSmithKline
      • Table 21: Insulet Enters Into Distribution Agreement With GlaxoSmithKline
      • Table 22: bioMerieux Signs Co-Development Agreement With GlaxoSmithKline
      • Table 23: Abbott Laboratories Enters Into An Agreement With GlaxoSmithKline
      • Table 24: bioMerieux Enters Into An Agreement With GlaxoSmithKline
      • Table 25: GlaxoSmithKline Signs Co-Development Agreement With Enigma Diagnostics
      • Table 26: DermTech International Enters Into Co-Development Agreement With Stiefel Laboratories
      • Table 27: OncoMethylome Sciences Enters Into Collaboration With GlaxoSmithKline Biologicals
      • Table 28: Thermo Fisher Scientific Acquires Qualigens Fine Chemicals GlaxoSmithKline Pharmaceuticals
      • Table 29: Enigma Diagnostics To Receive Equity Investment From GlaxoSmithKline
      • Table 30: GlaxoSmithKline Acquires CNS
      • Table 31: USD to Local Currency, Average Exchange Rate, 2010
    • 1.2 List of Figures
      • Figure 1: Metered Dose Inhaler Devices, Global, Market Share (%), 2010
      • Figure 2: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Global, Market Share (%), 2010
      • Figure 3: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Asia-Pacific, Market Share (%), 2010
      • Figure 4: GlaxoSmithKline plc, Metered Dose Inhaler Devices, Europe, Market Share (%), 2010
      • Figure 5: GlaxoSmithKline plc, Metered Dose Inhaler Devices, North America, Market Share (%), 2010
      • Figure 6: GlaxoSmithKline plc, Metered Dose Inhaler Devices, South and Central America, Market Share (%), 2010
      • Figure 7: GlaxoSmithKline plc, Deals Volume Summary, 2006 to YTD 2011
      • Figure 8: GlaxoSmithKline plc, Deals Summary By Region, 2006 to YTD 2011
+44 20 8816 8548

Ask a question about GlaxoSmithKline plc

Enter the characters you see in the picture below
Captcha